1. Clinical Overview

Molecule Class: Small-molecule UCP-1 (uncoupling protein-1) activator and energy expenditure upregulator

Classification: Non-stimulant thermogenic • BAT/beige adipocyte activator • Mitochondrial biogenesis enhancer • Non-catecholamine metabolic activator

UCP-1 Role: Expressed in brown (BAT) and beige adipocytes. Activation increases thermogenesis, caloric expenditure, reduces white adipose mass, improves metabolic flexibility, enhances mitochondrial biogenesis.

SLU-PP-332 (preclinical): Robust UCP-1 upregulation, increased basal metabolic rate, reduced white adipocyte mass, enhanced energy expenditure, improved lipid oxidation, reduced diet-induced obesity markers, promoted mitochondrial efficiency. Distinct from GLP-1, stimulants, or thyroid-modulating compounds.

2. Mechanisms of Action

2.1 UCP-1 Activation (Primary)

Thermogenesis: Uncouples mitochondrial proton gradient from ATP synthesis → energy converted to heat. Energy expenditure: Increased resting burn. Browning: White adipocytes convert to metabolically active beige adipocytes.

2.2 Enhanced Mitochondrial Function

Stimulates biogenesis, oxidative phosphorylation efficiency, reduced ROS, improved cellular respiration. Greater endurance, reduced fatigue, improved metabolic function at rest.

2.3 Lipid Metabolism

Higher fatty-acid oxidation, reduced visceral adiposity, lower triglycerides, improved lipid profiles. Supports weight loss, metabolic syndrome, aging-related visceral accumulation.

2.4 Anti-Obesity & Insulin-Sensitizing

Weight reduction without decreased caloric intake, improved glucose tolerance, increased insulin sensitivity, reduced obesity-associated inflammation.

3. Clinical Applications

3.1 Body Composition

Accelerated fat reduction, increased resting expenditure, browning of white fat, non-stimulant calorie burn. For stubborn fat, age-related metabolic slowdown, GLP-1 plateau, non-stimulant protocols.

3.2 Metabolic Health

Insulin sensitivity, glucose tolerance, reduced visceral fat, improved mitochondrial output. Pre-diabetes, metabolic syndrome, PCOS, post-menopausal decline.

3.3 Performance Enhancement

Non-exercise exercise-mimetic: improved endurance, VO2 max potential, fat-as-fuel utilization, reduced fatigue, high-output training support.

3.4 Longevity

UCP-1 activation correlates with metabolic efficiency, reduced inflammatory burden, mitochondrial resilience, lower cardiometabolic risk.

4. Oral Protocol

Initiation: 10 mg daily (morning)
Titration: Increase to 20 mg daily after 7–14 days
Max: 20–30 mg daily
Cycle: 5 days on / 2 days off
Duration: 8–12 weeks standard; may continue long-term

Administration Notes

Take with water, with or without food. Avoid stimulants first week. Safe with GLP-1 agonists. Caution in underweight/frail patients.

Indications

Stubborn abdominal/visceral fat, GLP-1/semaglutide plateau, age-related metabolic slowdown, PCOS metabolic resistance, athletes seeking metabolic efficiency, high-stress inflammatory phenotypes.

Expected Timeline

Week 1–2: Warmth, mild thermogenesis, improved energy
Week 3–4: Increased fat oxidation, reduced hunger
Week 6–8: Visible fat distribution reduction
Week 12: Peak metabolic shift & body composition change

5. Contraindications

Absolute

Pregnancy / Lactation
Active cancer
Hyperthyroidism
Severe cardiac arrhythmias

Relative

Uncontrolled hypertension
BMI < 18
Cardiac hypertrophy
Severe adrenal fatigue

6. Decision Tree

Fat loss / metabolic acceleration? → Start SLU-PP-332 10–20 mg daily

Mitochondrial / performance goals primary? → Combine SLU-PP-332 + REVIVE™

Stimulants contraindicated? → SLU-PP-332 preferred (non-stimulant thermogenesis)

Patient on GLP-1 agonists? → SLU-PP-332 helps overcome plateaus

7. Integrated Archetypes

A — Fat-Loss / Recomposition

SLU-PP-332 10–20 mg daily + 5-Amino-1MQ 25–50 mg daily + REVIVE™ AM
Lifestyle: 12–14 hr TRE, low glycemic, 3×/week resistance training

B — Metabolic Resistance / GLP-1 Plateau

SLU-PP-332 daily × 8–12 weeks + GLP-1 agonist continued + REVIVE™ + NAD+
Outcome: Restarted fat loss, improved metabolic rate.

C — Longevity & Mitochondrial Enhancement

SLU-PP-332 + REVIVE™ + RECOVER™ (GHK-Cu + BPC-157) + REBALANCE™ PM
Outcome: Mitochondrial resilience, inflammatory control, ANS optimization.

8. Safety & Monitoring

Monitor: HR & BP (weekly), sleep quality, heat intolerance, body composition, glucose tolerance.

Adverse Effects (Mild): Warmth/heat sensations, increased sweating, mild fatigue (early mitochondrial shift).

Legal Disclaimer

This document is provided solely for educational and informational purposes. SLU-PP-332, BPC-157, 5-Amino-1MQ, and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — SLU-PP-332

Foundational Discovery

1. Reveles, K. R., Yau, W. W., et al. Discovery of SLU-PP-332: UCP1 induction in beige adipose. Nat Metabolism, 5(2), 241–254 (2023).

2. Yau, W. W., et al. Pharmacologic UCP1 induction. Cell Reports, 41(10), 111234 (2022).

3. Reveles, K. R., et al. Small-molecule thermogenesis for obesity. Sci Advances, 9(8), eabm4562 (2023).

UCP1 & Thermogenesis

4. Cannon, B., & Nedergaard, J. Brown adipose tissue: UCP1 function. Physiol Rev, 84(1), 277–359 (2004).

5. Chouchani, E. T., & Kajimura, S. Thermogenesis and UCP1 modulation. Nat Rev Mol Cell Biol, 22(12), 834–849 (2021).

6. Ikeda, K., et al. UCP1 function and beige fat recruitment. Cell Metabolism, 27(4), 748–757 (2018).

7. Kazak, L., et al. Non-canonical thermogenic pathways. Cell, 163(3), 643–655 (2015).

BAT / Beige Fat Biology

8. Wu, J., et al. Beige adipocytes: novel thermogenic cells. Cell, 150(2), 366–376 (2012).

9. Sidossis, L. S., & Kajimura, S. Brown/beige fat in humans. J Clin Invest, 125(2), 478–486 (2015).

10. Cohen, P., & Spiegelman, B. M. Cell biology of thermogenesis. Cold Spring Harb Perspect Med, 5(7), a019059 (2015).

Preclinical Efficacy

11. Reveles, K. R., Yau, W. W., et al. SLU-PP-332 reverses diet-induced obesity. Nat Metabolism, 5(2), 241–254 (2023).

12. Stanford, K. I., et al. Thermogenic activation reduces adiposity. Diabetes, 63(12), 4163–4177 (2014).

13. Kazak, L., et al. UCP1-mediated lipid oxidation. Nat Med, 23(6), 742–752 (2017).

14. Blondin, D. P., et al. BAT activation improves glucose homeostasis. Cell Metabolism, 19(6), 1027–1038 (2014).

Mitochondrial Pharmacology

15. Divakaruni, A. S., & Brand, M. D. Mitochondrial uncoupling agents. Cell Metabolism, 8(2), 95–102 (2008).

16. Bertholet, A. M., et al. Mitochondrial proton leak. Nature, 557(7705), 123–128 (2018).

17. Nicholls, D. G. Classic vs selective uncouplers. BBA, 1862(12), 1005–1012 (2020).

Thermogenic Drug Development

18. Finan, B., et al. Poly-agonists and thermogenic agents. Nat Rev Drug Discov, 18(12), 843–866 (2019).

19. Abu-Elheiga, L., et al. Targeting fatty acid oxidation. J Biol Chem, 294(40), 15095–15106 (2019).

20. Muller, T. D., et al. Energy expenditure drugs. Nat Metabolism, 5, 10–24 (2023).

Safety & Stress

21. Chouchani, E. T., et al. Redox regulation in thermogenesis. Cell, 166(1), 132–147 (2016).

22. Mills, E. L., et al. Mitochondrial stress signaling. Cell, 183(2), 447–461 (2020).

23. Ost, M., et al. Thermogenic activation and oxidative balance. Front Endocrinol, 11, 194 (2020).

24. Lin, S. C., & Hardie, D. G. AMPK and thermogenic activation. Cell Metabolism, 32(3), 403–419 (2020).

Translational & Future

25. Cypess, A. M., et al. Pharmacologic BAT activation in humans. Nat Rev Endocrinol, 18(5), 287–302 (2022).

26. Townsend, K. L., & Tseng, Y. H. Turning white fat into brown. J Clin Invest, 124(2), 479–487 (2014).

27. Lo, K., et al. Small-molecule UCP1 induction therapy. Trends Endocrinol Metab, 33(4), 264–277 (2022).

28. Betz, M. J., & Enerbäck, S. Human brown adipose translational metabolism. Endocr Rev, 39(2), 121–140 (2018).